Medical Care
Fabry Disease Therapeutic - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Sep 11, 24
- ID: 549596
- Pages: 130
- Figures: 201
- Views: 3
The global market for Fabry Disease Therapeutic was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Fabry Disease Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Fabry Disease Therapeutic by region & country, by Type, and by Application.
The Fabry Disease Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fabry Disease Therapeutic.
Market Segmentation
By Company
Amicus therapeutics
Takeda
Genzyme-Sanofi
Protalix
Sanofi-Aventis LLC
Novartis Pharmaceuticals
Pfizer
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Amgen Inc.
Teva pharmaceutical Industries Ltd.
Merc & Co.
AbbVie Inc.
Takeda Pharmaceutical Co. Ltd.
Green Cross Corp.
Segment by Type:
Enzyme Replacement Therapy
Alternative therapies
Segment by Application
Hospitals
Clinics
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Fabry Disease Therapeutic manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Fabry Disease Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Fabry Disease Therapeutic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Fabry Disease Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Fabry Disease Therapeutic by region & country, by Type, and by Application.
The Fabry Disease Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fabry Disease Therapeutic.
Market Segmentation
By Company
Amicus therapeutics
Takeda
Genzyme-Sanofi
Protalix
Sanofi-Aventis LLC
Novartis Pharmaceuticals
Pfizer
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Amgen Inc.
Teva pharmaceutical Industries Ltd.
Merc & Co.
AbbVie Inc.
Takeda Pharmaceutical Co. Ltd.
Green Cross Corp.
Segment by Type:
Enzyme Replacement Therapy
Alternative therapies
Segment by Application
Hospitals
Clinics
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Fabry Disease Therapeutic manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Fabry Disease Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Fabry Disease Therapeutic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Fabry Disease Therapeutic Product Introduction
1.2 Global Fabry Disease Therapeutic Market Size Forecast
1.3 Fabry Disease Therapeutic Market Trends & Drivers
1.3.1 Fabry Disease Therapeutic Industry Trends
1.3.2 Fabry Disease Therapeutic Market Drivers & Opportunity
1.3.3 Fabry Disease Therapeutic Market Challenges
1.3.4 Fabry Disease Therapeutic Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Fabry Disease Therapeutic Players Revenue Ranking (2023)
2.2 Global Fabry Disease Therapeutic Revenue by Company (2019-2024)
2.3 Key Companies Fabry Disease Therapeutic Manufacturing Base Distribution and Headquarters
2.4 Key Companies Fabry Disease Therapeutic Product Offered
2.5 Key Companies Time to Begin Mass Production of Fabry Disease Therapeutic
2.6 Fabry Disease Therapeutic Market Competitive Analysis
2.6.1 Fabry Disease Therapeutic Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Fabry Disease Therapeutic Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fabry Disease Therapeutic as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Enzyme Replacement Therapy
3.1.2 Alternative therapies
3.2 Global Fabry Disease Therapeutic Sales Value by Type
3.2.1 Global Fabry Disease Therapeutic Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Fabry Disease Therapeutic Sales Value, by Type (2019-2030)
3.2.3 Global Fabry Disease Therapeutic Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Other
4.2 Global Fabry Disease Therapeutic Sales Value by Application
4.2.1 Global Fabry Disease Therapeutic Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Fabry Disease Therapeutic Sales Value, by Application (2019-2030)
4.2.3 Global Fabry Disease Therapeutic Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Fabry Disease Therapeutic Sales Value by Region
5.1.1 Global Fabry Disease Therapeutic Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Fabry Disease Therapeutic Sales Value by Region (2019-2024)
5.1.3 Global Fabry Disease Therapeutic Sales Value by Region (2025-2030)
5.1.4 Global Fabry Disease Therapeutic Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Fabry Disease Therapeutic Sales Value, 2019-2030
5.2.2 North America Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Fabry Disease Therapeutic Sales Value, 2019-2030
5.3.2 Europe Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Fabry Disease Therapeutic Sales Value, 2019-2030
5.4.2 Asia Pacific Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Fabry Disease Therapeutic Sales Value, 2019-2030
5.5.2 South America Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Fabry Disease Therapeutic Sales Value, 2019-2030
5.6.2 Middle East & Africa Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Fabry Disease Therapeutic Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Fabry Disease Therapeutic Sales Value
6.3 United States
6.3.1 United States Fabry Disease Therapeutic Sales Value, 2019-2030
6.3.2 United States Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Fabry Disease Therapeutic Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Fabry Disease Therapeutic Sales Value, 2019-2030
6.4.2 Europe Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Fabry Disease Therapeutic Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Fabry Disease Therapeutic Sales Value, 2019-2030
6.5.2 China Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
6.5.3 China Fabry Disease Therapeutic Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Fabry Disease Therapeutic Sales Value, 2019-2030
6.6.2 Japan Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Fabry Disease Therapeutic Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Fabry Disease Therapeutic Sales Value, 2019-2030
6.7.2 South Korea Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Fabry Disease Therapeutic Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Fabry Disease Therapeutic Sales Value, 2019-2030
6.8.2 Southeast Asia Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Fabry Disease Therapeutic Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Fabry Disease Therapeutic Sales Value, 2019-2030
6.9.2 India Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
6.9.3 India Fabry Disease Therapeutic Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Amicus therapeutics
7.1.1 Amicus therapeutics Profile
7.1.2 Amicus therapeutics Main Business
7.1.3 Amicus therapeutics Fabry Disease Therapeutic Products, Services and Solutions
7.1.4 Amicus therapeutics Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.1.5 Amicus therapeutics Recent Developments
7.2 Takeda
7.2.1 Takeda Profile
7.2.2 Takeda Main Business
7.2.3 Takeda Fabry Disease Therapeutic Products, Services and Solutions
7.2.4 Takeda Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.2.5 Takeda Recent Developments
7.3 Genzyme-Sanofi
7.3.1 Genzyme-Sanofi Profile
7.3.2 Genzyme-Sanofi Main Business
7.3.3 Genzyme-Sanofi Fabry Disease Therapeutic Products, Services and Solutions
7.3.4 Genzyme-Sanofi Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.3.5 Protalix Recent Developments
7.4 Protalix
7.4.1 Protalix Profile
7.4.2 Protalix Main Business
7.4.3 Protalix Fabry Disease Therapeutic Products, Services and Solutions
7.4.4 Protalix Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.4.5 Protalix Recent Developments
7.5 Sanofi-Aventis LLC
7.5.1 Sanofi-Aventis LLC Profile
7.5.2 Sanofi-Aventis LLC Main Business
7.5.3 Sanofi-Aventis LLC Fabry Disease Therapeutic Products, Services and Solutions
7.5.4 Sanofi-Aventis LLC Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.5.5 Sanofi-Aventis LLC Recent Developments
7.6 Novartis Pharmaceuticals
7.6.1 Novartis Pharmaceuticals Profile
7.6.2 Novartis Pharmaceuticals Main Business
7.6.3 Novartis Pharmaceuticals Fabry Disease Therapeutic Products, Services and Solutions
7.6.4 Novartis Pharmaceuticals Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.6.5 Novartis Pharmaceuticals Recent Developments
7.7 Pfizer
7.7.1 Pfizer Profile
7.7.2 Pfizer Main Business
7.7.3 Pfizer Fabry Disease Therapeutic Products, Services and Solutions
7.7.4 Pfizer Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.7.5 Pfizer Recent Developments
7.8 Bristol-Myers Squibb Company
7.8.1 Bristol-Myers Squibb Company Profile
7.8.2 Bristol-Myers Squibb Company Main Business
7.8.3 Bristol-Myers Squibb Company Fabry Disease Therapeutic Products, Services and Solutions
7.8.4 Bristol-Myers Squibb Company Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.8.5 Bristol-Myers Squibb Company Recent Developments
7.9 GlaxoSmithKline plc
7.9.1 GlaxoSmithKline plc Profile
7.9.2 GlaxoSmithKline plc Main Business
7.9.3 GlaxoSmithKline plc Fabry Disease Therapeutic Products, Services and Solutions
7.9.4 GlaxoSmithKline plc Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.9.5 GlaxoSmithKline plc Recent Developments
7.10 Amgen Inc.
7.10.1 Amgen Inc. Profile
7.10.2 Amgen Inc. Main Business
7.10.3 Amgen Inc. Fabry Disease Therapeutic Products, Services and Solutions
7.10.4 Amgen Inc. Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.10.5 Amgen Inc. Recent Developments
7.11 Teva pharmaceutical Industries Ltd.
7.11.1 Teva pharmaceutical Industries Ltd. Profile
7.11.2 Teva pharmaceutical Industries Ltd. Main Business
7.11.3 Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Products, Services and Solutions
7.11.4 Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.11.5 Teva pharmaceutical Industries Ltd. Recent Developments
7.12 Merc & Co.
7.12.1 Merc & Co. Profile
7.12.2 Merc & Co. Main Business
7.12.3 Merc & Co. Fabry Disease Therapeutic Products, Services and Solutions
7.12.4 Merc & Co. Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.12.5 Merc & Co. Recent Developments
7.13 AbbVie Inc.
7.13.1 AbbVie Inc. Profile
7.13.2 AbbVie Inc. Main Business
7.13.3 AbbVie Inc. Fabry Disease Therapeutic Products, Services and Solutions
7.13.4 AbbVie Inc. Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.13.5 AbbVie Inc. Recent Developments
7.14 Takeda Pharmaceutical Co. Ltd.
7.14.1 Takeda Pharmaceutical Co. Ltd. Profile
7.14.2 Takeda Pharmaceutical Co. Ltd. Main Business
7.14.3 Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Products, Services and Solutions
7.14.4 Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.14.5 Takeda Pharmaceutical Co. Ltd. Recent Developments
7.15 Green Cross Corp.
7.15.1 Green Cross Corp. Profile
7.15.2 Green Cross Corp. Main Business
7.15.3 Green Cross Corp. Fabry Disease Therapeutic Products, Services and Solutions
7.15.4 Green Cross Corp. Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.15.5 Green Cross Corp. Recent Developments
8 Industry Chain Analysis
8.1 Fabry Disease Therapeutic Industrial Chain
8.2 Fabry Disease Therapeutic Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Fabry Disease Therapeutic Sales Model
8.5.2 Sales Channel
8.5.3 Fabry Disease Therapeutic Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Fabry Disease Therapeutic Product Introduction
1.2 Global Fabry Disease Therapeutic Market Size Forecast
1.3 Fabry Disease Therapeutic Market Trends & Drivers
1.3.1 Fabry Disease Therapeutic Industry Trends
1.3.2 Fabry Disease Therapeutic Market Drivers & Opportunity
1.3.3 Fabry Disease Therapeutic Market Challenges
1.3.4 Fabry Disease Therapeutic Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Fabry Disease Therapeutic Players Revenue Ranking (2023)
2.2 Global Fabry Disease Therapeutic Revenue by Company (2019-2024)
2.3 Key Companies Fabry Disease Therapeutic Manufacturing Base Distribution and Headquarters
2.4 Key Companies Fabry Disease Therapeutic Product Offered
2.5 Key Companies Time to Begin Mass Production of Fabry Disease Therapeutic
2.6 Fabry Disease Therapeutic Market Competitive Analysis
2.6.1 Fabry Disease Therapeutic Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Fabry Disease Therapeutic Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fabry Disease Therapeutic as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Enzyme Replacement Therapy
3.1.2 Alternative therapies
3.2 Global Fabry Disease Therapeutic Sales Value by Type
3.2.1 Global Fabry Disease Therapeutic Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Fabry Disease Therapeutic Sales Value, by Type (2019-2030)
3.2.3 Global Fabry Disease Therapeutic Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Other
4.2 Global Fabry Disease Therapeutic Sales Value by Application
4.2.1 Global Fabry Disease Therapeutic Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Fabry Disease Therapeutic Sales Value, by Application (2019-2030)
4.2.3 Global Fabry Disease Therapeutic Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Fabry Disease Therapeutic Sales Value by Region
5.1.1 Global Fabry Disease Therapeutic Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Fabry Disease Therapeutic Sales Value by Region (2019-2024)
5.1.3 Global Fabry Disease Therapeutic Sales Value by Region (2025-2030)
5.1.4 Global Fabry Disease Therapeutic Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Fabry Disease Therapeutic Sales Value, 2019-2030
5.2.2 North America Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Fabry Disease Therapeutic Sales Value, 2019-2030
5.3.2 Europe Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Fabry Disease Therapeutic Sales Value, 2019-2030
5.4.2 Asia Pacific Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Fabry Disease Therapeutic Sales Value, 2019-2030
5.5.2 South America Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Fabry Disease Therapeutic Sales Value, 2019-2030
5.6.2 Middle East & Africa Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Fabry Disease Therapeutic Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Fabry Disease Therapeutic Sales Value
6.3 United States
6.3.1 United States Fabry Disease Therapeutic Sales Value, 2019-2030
6.3.2 United States Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Fabry Disease Therapeutic Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Fabry Disease Therapeutic Sales Value, 2019-2030
6.4.2 Europe Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Fabry Disease Therapeutic Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Fabry Disease Therapeutic Sales Value, 2019-2030
6.5.2 China Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
6.5.3 China Fabry Disease Therapeutic Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Fabry Disease Therapeutic Sales Value, 2019-2030
6.6.2 Japan Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Fabry Disease Therapeutic Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Fabry Disease Therapeutic Sales Value, 2019-2030
6.7.2 South Korea Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Fabry Disease Therapeutic Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Fabry Disease Therapeutic Sales Value, 2019-2030
6.8.2 Southeast Asia Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Fabry Disease Therapeutic Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Fabry Disease Therapeutic Sales Value, 2019-2030
6.9.2 India Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
6.9.3 India Fabry Disease Therapeutic Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Amicus therapeutics
7.1.1 Amicus therapeutics Profile
7.1.2 Amicus therapeutics Main Business
7.1.3 Amicus therapeutics Fabry Disease Therapeutic Products, Services and Solutions
7.1.4 Amicus therapeutics Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.1.5 Amicus therapeutics Recent Developments
7.2 Takeda
7.2.1 Takeda Profile
7.2.2 Takeda Main Business
7.2.3 Takeda Fabry Disease Therapeutic Products, Services and Solutions
7.2.4 Takeda Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.2.5 Takeda Recent Developments
7.3 Genzyme-Sanofi
7.3.1 Genzyme-Sanofi Profile
7.3.2 Genzyme-Sanofi Main Business
7.3.3 Genzyme-Sanofi Fabry Disease Therapeutic Products, Services and Solutions
7.3.4 Genzyme-Sanofi Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.3.5 Protalix Recent Developments
7.4 Protalix
7.4.1 Protalix Profile
7.4.2 Protalix Main Business
7.4.3 Protalix Fabry Disease Therapeutic Products, Services and Solutions
7.4.4 Protalix Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.4.5 Protalix Recent Developments
7.5 Sanofi-Aventis LLC
7.5.1 Sanofi-Aventis LLC Profile
7.5.2 Sanofi-Aventis LLC Main Business
7.5.3 Sanofi-Aventis LLC Fabry Disease Therapeutic Products, Services and Solutions
7.5.4 Sanofi-Aventis LLC Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.5.5 Sanofi-Aventis LLC Recent Developments
7.6 Novartis Pharmaceuticals
7.6.1 Novartis Pharmaceuticals Profile
7.6.2 Novartis Pharmaceuticals Main Business
7.6.3 Novartis Pharmaceuticals Fabry Disease Therapeutic Products, Services and Solutions
7.6.4 Novartis Pharmaceuticals Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.6.5 Novartis Pharmaceuticals Recent Developments
7.7 Pfizer
7.7.1 Pfizer Profile
7.7.2 Pfizer Main Business
7.7.3 Pfizer Fabry Disease Therapeutic Products, Services and Solutions
7.7.4 Pfizer Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.7.5 Pfizer Recent Developments
7.8 Bristol-Myers Squibb Company
7.8.1 Bristol-Myers Squibb Company Profile
7.8.2 Bristol-Myers Squibb Company Main Business
7.8.3 Bristol-Myers Squibb Company Fabry Disease Therapeutic Products, Services and Solutions
7.8.4 Bristol-Myers Squibb Company Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.8.5 Bristol-Myers Squibb Company Recent Developments
7.9 GlaxoSmithKline plc
7.9.1 GlaxoSmithKline plc Profile
7.9.2 GlaxoSmithKline plc Main Business
7.9.3 GlaxoSmithKline plc Fabry Disease Therapeutic Products, Services and Solutions
7.9.4 GlaxoSmithKline plc Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.9.5 GlaxoSmithKline plc Recent Developments
7.10 Amgen Inc.
7.10.1 Amgen Inc. Profile
7.10.2 Amgen Inc. Main Business
7.10.3 Amgen Inc. Fabry Disease Therapeutic Products, Services and Solutions
7.10.4 Amgen Inc. Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.10.5 Amgen Inc. Recent Developments
7.11 Teva pharmaceutical Industries Ltd.
7.11.1 Teva pharmaceutical Industries Ltd. Profile
7.11.2 Teva pharmaceutical Industries Ltd. Main Business
7.11.3 Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Products, Services and Solutions
7.11.4 Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.11.5 Teva pharmaceutical Industries Ltd. Recent Developments
7.12 Merc & Co.
7.12.1 Merc & Co. Profile
7.12.2 Merc & Co. Main Business
7.12.3 Merc & Co. Fabry Disease Therapeutic Products, Services and Solutions
7.12.4 Merc & Co. Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.12.5 Merc & Co. Recent Developments
7.13 AbbVie Inc.
7.13.1 AbbVie Inc. Profile
7.13.2 AbbVie Inc. Main Business
7.13.3 AbbVie Inc. Fabry Disease Therapeutic Products, Services and Solutions
7.13.4 AbbVie Inc. Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.13.5 AbbVie Inc. Recent Developments
7.14 Takeda Pharmaceutical Co. Ltd.
7.14.1 Takeda Pharmaceutical Co. Ltd. Profile
7.14.2 Takeda Pharmaceutical Co. Ltd. Main Business
7.14.3 Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Products, Services and Solutions
7.14.4 Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.14.5 Takeda Pharmaceutical Co. Ltd. Recent Developments
7.15 Green Cross Corp.
7.15.1 Green Cross Corp. Profile
7.15.2 Green Cross Corp. Main Business
7.15.3 Green Cross Corp. Fabry Disease Therapeutic Products, Services and Solutions
7.15.4 Green Cross Corp. Fabry Disease Therapeutic Revenue (US$ Million) & (2019-2024)
7.15.5 Green Cross Corp. Recent Developments
8 Industry Chain Analysis
8.1 Fabry Disease Therapeutic Industrial Chain
8.2 Fabry Disease Therapeutic Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Fabry Disease Therapeutic Sales Model
8.5.2 Sales Channel
8.5.3 Fabry Disease Therapeutic Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Fabry Disease Therapeutic Market Trends
Table 2. Fabry Disease Therapeutic Market Drivers & Opportunity
Table 3. Fabry Disease Therapeutic Market Challenges
Table 4. Fabry Disease Therapeutic Market Restraints
Table 5. Global Fabry Disease Therapeutic Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Fabry Disease Therapeutic Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Fabry Disease Therapeutic Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Fabry Disease Therapeutic Product Type
Table 9. Key Companies Time to Begin Mass Production of Fabry Disease Therapeutic
Table 10. Global Fabry Disease Therapeutic Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fabry Disease Therapeutic as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Fabry Disease Therapeutic Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Fabry Disease Therapeutic Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Fabry Disease Therapeutic Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Fabry Disease Therapeutic Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Fabry Disease Therapeutic Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Fabry Disease Therapeutic Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Fabry Disease Therapeutic Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Fabry Disease Therapeutic Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Fabry Disease Therapeutic Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Fabry Disease Therapeutic Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Fabry Disease Therapeutic Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Fabry Disease Therapeutic Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Fabry Disease Therapeutic Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Fabry Disease Therapeutic Sales Value by Region (2019-2024) & (%)
Table 27. Global Fabry Disease Therapeutic Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Fabry Disease Therapeutic Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Fabry Disease Therapeutic Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Fabry Disease Therapeutic Sales Value, (2025-2030) & (US$ Million)
Table 31. Amicus therapeutics Basic Information List
Table 32. Amicus therapeutics Description and Business Overview
Table 33. Amicus therapeutics Fabry Disease Therapeutic Products, Services and Solutions
Table 34. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Amicus therapeutics (2019-2024)
Table 35. Amicus therapeutics Recent Developments
Table 36. Takeda Basic Information List
Table 37. Takeda Description and Business Overview
Table 38. Takeda Fabry Disease Therapeutic Products, Services and Solutions
Table 39. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Takeda (2019-2024)
Table 40. Takeda Recent Developments
Table 41. Genzyme-Sanofi Basic Information List
Table 42. Genzyme-Sanofi Description and Business Overview
Table 43. Genzyme-Sanofi Fabry Disease Therapeutic Products, Services and Solutions
Table 44. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Genzyme-Sanofi (2019-2024)
Table 45. Genzyme-Sanofi Recent Developments
Table 46. Protalix Basic Information List
Table 47. Protalix Description and Business Overview
Table 48. Protalix Fabry Disease Therapeutic Products, Services and Solutions
Table 49. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Protalix (2019-2024)
Table 50. Protalix Recent Developments
Table 51. Sanofi-Aventis LLC Basic Information List
Table 52. Sanofi-Aventis LLC Description and Business Overview
Table 53. Sanofi-Aventis LLC Fabry Disease Therapeutic Products, Services and Solutions
Table 54. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Sanofi-Aventis LLC (2019-2024)
Table 55. Sanofi-Aventis LLC Recent Developments
Table 56. Novartis Pharmaceuticals Basic Information List
Table 57. Novartis Pharmaceuticals Description and Business Overview
Table 58. Novartis Pharmaceuticals Fabry Disease Therapeutic Products, Services and Solutions
Table 59. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Novartis Pharmaceuticals (2019-2024)
Table 60. Novartis Pharmaceuticals Recent Developments
Table 61. Pfizer Basic Information List
Table 62. Pfizer Description and Business Overview
Table 63. Pfizer Fabry Disease Therapeutic Products, Services and Solutions
Table 64. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Pfizer (2019-2024)
Table 65. Pfizer Recent Developments
Table 66. Bristol-Myers Squibb Company Basic Information List
Table 67. Bristol-Myers Squibb Company Description and Business Overview
Table 68. Bristol-Myers Squibb Company Fabry Disease Therapeutic Products, Services and Solutions
Table 69. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Bristol-Myers Squibb Company (2019-2024)
Table 70. Bristol-Myers Squibb Company Recent Developments
Table 71. GlaxoSmithKline plc Basic Information List
Table 72. GlaxoSmithKline plc Description and Business Overview
Table 73. GlaxoSmithKline plc Fabry Disease Therapeutic Products, Services and Solutions
Table 74. Revenue (US$ Million) in Fabry Disease Therapeutic Business of GlaxoSmithKline plc (2019-2024)
Table 75. GlaxoSmithKline plc Recent Developments
Table 76. Amgen Inc. Basic Information List
Table 77. Amgen Inc. Description and Business Overview
Table 78. Amgen Inc. Fabry Disease Therapeutic Products, Services and Solutions
Table 79. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Amgen Inc. (2019-2024)
Table 80. Amgen Inc. Recent Developments
Table 81. Teva pharmaceutical Industries Ltd. Basic Information List
Table 82. Teva pharmaceutical Industries Ltd. Description and Business Overview
Table 83. Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Products, Services and Solutions
Table 84. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Teva pharmaceutical Industries Ltd. (2019-2024)
Table 85. Teva pharmaceutical Industries Ltd. Recent Developments
Table 86. Merc & Co. Basic Information List
Table 87. Merc & Co. Description and Business Overview
Table 88. Merc & Co. Fabry Disease Therapeutic Products, Services and Solutions
Table 89. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Merc & Co. (2019-2024)
Table 90. Merc & Co. Recent Developments
Table 91. AbbVie Inc. Basic Information List
Table 92. AbbVie Inc. Description and Business Overview
Table 93. AbbVie Inc. Fabry Disease Therapeutic Products, Services and Solutions
Table 94. Revenue (US$ Million) in Fabry Disease Therapeutic Business of AbbVie Inc. (2019-2024)
Table 95. AbbVie Inc. Recent Developments
Table 96. Takeda Pharmaceutical Co. Ltd. Basic Information List
Table 97. Takeda Pharmaceutical Co. Ltd. Description and Business Overview
Table 98. Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Products, Services and Solutions
Table 99. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Takeda Pharmaceutical Co. Ltd. (2019-2024)
Table 100. Takeda Pharmaceutical Co. Ltd. Recent Developments
Table 101. Green Cross Corp. Basic Information List
Table 102. Green Cross Corp. Description and Business Overview
Table 103. Green Cross Corp. Fabry Disease Therapeutic Products, Services and Solutions
Table 104. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Green Cross Corp. (2019-2024)
Table 105. Green Cross Corp. Recent Developments
Table 106. Key Raw Materials Lists
Table 107. Raw Materials Key Suppliers Lists
Table 108. Fabry Disease Therapeutic Downstream Customers
Table 109. Fabry Disease Therapeutic Distributors List
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
Table 113. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Fabry Disease Therapeutic Product Picture
Figure 2. Global Fabry Disease Therapeutic Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Fabry Disease Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 4. Fabry Disease Therapeutic Report Years Considered
Figure 5. Global Fabry Disease Therapeutic Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Fabry Disease Therapeutic Revenue in 2023
Figure 7. Fabry Disease Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Enzyme Replacement Therapy Picture
Figure 9. Alternative therapies Picture
Figure 10. Global Fabry Disease Therapeutic Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Fabry Disease Therapeutic Sales Value Market Share by Type, 2023 & 2030
Figure 12. Product Picture of Hospitals
Figure 13. Product Picture of Clinics
Figure 14. Product Picture of Other
Figure 15. Global Fabry Disease Therapeutic Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Fabry Disease Therapeutic Sales Value Market Share by Application, 2023 & 2030
Figure 17. North America Fabry Disease Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 18. North America Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 19. Europe Fabry Disease Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 20. Europe Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 21. Asia Pacific Fabry Disease Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 22. Asia Pacific Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 23. South America Fabry Disease Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 24. South America Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 25. Middle East & Africa Fabry Disease Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 26. Middle East & Africa Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 27. Key Countries/Regions Fabry Disease Therapeutic Sales Value (%), (2019-2030)
Figure 28. United States Fabry Disease Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 29. United States Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 30. United States Fabry Disease Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 31. Europe Fabry Disease Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 32. Europe Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 33. Europe Fabry Disease Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 34. China Fabry Disease Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 35. China Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 36. China Fabry Disease Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 37. Japan Fabry Disease Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 38. Japan Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 39. Japan Fabry Disease Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 40. South Korea Fabry Disease Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 41. South Korea Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 42. South Korea Fabry Disease Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 43. Southeast Asia Fabry Disease Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 44. Southeast Asia Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 45. Southeast Asia Fabry Disease Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 46. India Fabry Disease Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 47. India Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 48. India Fabry Disease Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 49. Fabry Disease Therapeutic Industrial Chain
Figure 50. Fabry Disease Therapeutic Manufacturing Cost Structure
Figure 51. Channels of Distribution (Direct Sales, and Distribution)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Table 1. Fabry Disease Therapeutic Market Trends
Table 2. Fabry Disease Therapeutic Market Drivers & Opportunity
Table 3. Fabry Disease Therapeutic Market Challenges
Table 4. Fabry Disease Therapeutic Market Restraints
Table 5. Global Fabry Disease Therapeutic Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Fabry Disease Therapeutic Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Fabry Disease Therapeutic Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Fabry Disease Therapeutic Product Type
Table 9. Key Companies Time to Begin Mass Production of Fabry Disease Therapeutic
Table 10. Global Fabry Disease Therapeutic Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fabry Disease Therapeutic as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Fabry Disease Therapeutic Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Fabry Disease Therapeutic Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Fabry Disease Therapeutic Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Fabry Disease Therapeutic Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Fabry Disease Therapeutic Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Fabry Disease Therapeutic Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Fabry Disease Therapeutic Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Fabry Disease Therapeutic Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Fabry Disease Therapeutic Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Fabry Disease Therapeutic Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Fabry Disease Therapeutic Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Fabry Disease Therapeutic Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Fabry Disease Therapeutic Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Fabry Disease Therapeutic Sales Value by Region (2019-2024) & (%)
Table 27. Global Fabry Disease Therapeutic Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Fabry Disease Therapeutic Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Fabry Disease Therapeutic Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Fabry Disease Therapeutic Sales Value, (2025-2030) & (US$ Million)
Table 31. Amicus therapeutics Basic Information List
Table 32. Amicus therapeutics Description and Business Overview
Table 33. Amicus therapeutics Fabry Disease Therapeutic Products, Services and Solutions
Table 34. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Amicus therapeutics (2019-2024)
Table 35. Amicus therapeutics Recent Developments
Table 36. Takeda Basic Information List
Table 37. Takeda Description and Business Overview
Table 38. Takeda Fabry Disease Therapeutic Products, Services and Solutions
Table 39. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Takeda (2019-2024)
Table 40. Takeda Recent Developments
Table 41. Genzyme-Sanofi Basic Information List
Table 42. Genzyme-Sanofi Description and Business Overview
Table 43. Genzyme-Sanofi Fabry Disease Therapeutic Products, Services and Solutions
Table 44. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Genzyme-Sanofi (2019-2024)
Table 45. Genzyme-Sanofi Recent Developments
Table 46. Protalix Basic Information List
Table 47. Protalix Description and Business Overview
Table 48. Protalix Fabry Disease Therapeutic Products, Services and Solutions
Table 49. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Protalix (2019-2024)
Table 50. Protalix Recent Developments
Table 51. Sanofi-Aventis LLC Basic Information List
Table 52. Sanofi-Aventis LLC Description and Business Overview
Table 53. Sanofi-Aventis LLC Fabry Disease Therapeutic Products, Services and Solutions
Table 54. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Sanofi-Aventis LLC (2019-2024)
Table 55. Sanofi-Aventis LLC Recent Developments
Table 56. Novartis Pharmaceuticals Basic Information List
Table 57. Novartis Pharmaceuticals Description and Business Overview
Table 58. Novartis Pharmaceuticals Fabry Disease Therapeutic Products, Services and Solutions
Table 59. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Novartis Pharmaceuticals (2019-2024)
Table 60. Novartis Pharmaceuticals Recent Developments
Table 61. Pfizer Basic Information List
Table 62. Pfizer Description and Business Overview
Table 63. Pfizer Fabry Disease Therapeutic Products, Services and Solutions
Table 64. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Pfizer (2019-2024)
Table 65. Pfizer Recent Developments
Table 66. Bristol-Myers Squibb Company Basic Information List
Table 67. Bristol-Myers Squibb Company Description and Business Overview
Table 68. Bristol-Myers Squibb Company Fabry Disease Therapeutic Products, Services and Solutions
Table 69. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Bristol-Myers Squibb Company (2019-2024)
Table 70. Bristol-Myers Squibb Company Recent Developments
Table 71. GlaxoSmithKline plc Basic Information List
Table 72. GlaxoSmithKline plc Description and Business Overview
Table 73. GlaxoSmithKline plc Fabry Disease Therapeutic Products, Services and Solutions
Table 74. Revenue (US$ Million) in Fabry Disease Therapeutic Business of GlaxoSmithKline plc (2019-2024)
Table 75. GlaxoSmithKline plc Recent Developments
Table 76. Amgen Inc. Basic Information List
Table 77. Amgen Inc. Description and Business Overview
Table 78. Amgen Inc. Fabry Disease Therapeutic Products, Services and Solutions
Table 79. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Amgen Inc. (2019-2024)
Table 80. Amgen Inc. Recent Developments
Table 81. Teva pharmaceutical Industries Ltd. Basic Information List
Table 82. Teva pharmaceutical Industries Ltd. Description and Business Overview
Table 83. Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Products, Services and Solutions
Table 84. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Teva pharmaceutical Industries Ltd. (2019-2024)
Table 85. Teva pharmaceutical Industries Ltd. Recent Developments
Table 86. Merc & Co. Basic Information List
Table 87. Merc & Co. Description and Business Overview
Table 88. Merc & Co. Fabry Disease Therapeutic Products, Services and Solutions
Table 89. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Merc & Co. (2019-2024)
Table 90. Merc & Co. Recent Developments
Table 91. AbbVie Inc. Basic Information List
Table 92. AbbVie Inc. Description and Business Overview
Table 93. AbbVie Inc. Fabry Disease Therapeutic Products, Services and Solutions
Table 94. Revenue (US$ Million) in Fabry Disease Therapeutic Business of AbbVie Inc. (2019-2024)
Table 95. AbbVie Inc. Recent Developments
Table 96. Takeda Pharmaceutical Co. Ltd. Basic Information List
Table 97. Takeda Pharmaceutical Co. Ltd. Description and Business Overview
Table 98. Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Products, Services and Solutions
Table 99. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Takeda Pharmaceutical Co. Ltd. (2019-2024)
Table 100. Takeda Pharmaceutical Co. Ltd. Recent Developments
Table 101. Green Cross Corp. Basic Information List
Table 102. Green Cross Corp. Description and Business Overview
Table 103. Green Cross Corp. Fabry Disease Therapeutic Products, Services and Solutions
Table 104. Revenue (US$ Million) in Fabry Disease Therapeutic Business of Green Cross Corp. (2019-2024)
Table 105. Green Cross Corp. Recent Developments
Table 106. Key Raw Materials Lists
Table 107. Raw Materials Key Suppliers Lists
Table 108. Fabry Disease Therapeutic Downstream Customers
Table 109. Fabry Disease Therapeutic Distributors List
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
Table 113. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Fabry Disease Therapeutic Product Picture
Figure 2. Global Fabry Disease Therapeutic Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Fabry Disease Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 4. Fabry Disease Therapeutic Report Years Considered
Figure 5. Global Fabry Disease Therapeutic Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Fabry Disease Therapeutic Revenue in 2023
Figure 7. Fabry Disease Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Enzyme Replacement Therapy Picture
Figure 9. Alternative therapies Picture
Figure 10. Global Fabry Disease Therapeutic Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Fabry Disease Therapeutic Sales Value Market Share by Type, 2023 & 2030
Figure 12. Product Picture of Hospitals
Figure 13. Product Picture of Clinics
Figure 14. Product Picture of Other
Figure 15. Global Fabry Disease Therapeutic Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Fabry Disease Therapeutic Sales Value Market Share by Application, 2023 & 2030
Figure 17. North America Fabry Disease Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 18. North America Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 19. Europe Fabry Disease Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 20. Europe Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 21. Asia Pacific Fabry Disease Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 22. Asia Pacific Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 23. South America Fabry Disease Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 24. South America Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 25. Middle East & Africa Fabry Disease Therapeutic Sales Value (2019-2030) & (US$ Million)
Figure 26. Middle East & Africa Fabry Disease Therapeutic Sales Value by Country (%), 2023 VS 2030
Figure 27. Key Countries/Regions Fabry Disease Therapeutic Sales Value (%), (2019-2030)
Figure 28. United States Fabry Disease Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 29. United States Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 30. United States Fabry Disease Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 31. Europe Fabry Disease Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 32. Europe Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 33. Europe Fabry Disease Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 34. China Fabry Disease Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 35. China Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 36. China Fabry Disease Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 37. Japan Fabry Disease Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 38. Japan Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 39. Japan Fabry Disease Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 40. South Korea Fabry Disease Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 41. South Korea Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 42. South Korea Fabry Disease Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 43. Southeast Asia Fabry Disease Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 44. Southeast Asia Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 45. Southeast Asia Fabry Disease Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 46. India Fabry Disease Therapeutic Sales Value, (2019-2030) & (US$ Million)
Figure 47. India Fabry Disease Therapeutic Sales Value by Type (%), 2023 VS 2030
Figure 48. India Fabry Disease Therapeutic Sales Value by Application (%), 2023 VS 2030
Figure 49. Fabry Disease Therapeutic Industrial Chain
Figure 50. Fabry Disease Therapeutic Manufacturing Cost Structure
Figure 51. Channels of Distribution (Direct Sales, and Distribution)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
DigitalBroadcast and Cinematography Cameras Lease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Mobile and Web Event Analytics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Business Information - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232